Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0843
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients ; volume:89 ; number:6 ; day:25 ; month:4 ; year:2022 ; pages:785-793 ; date:6.2022
Cancer chemotherapy and pharmacology ; 89, Heft 6 (25.4.2022), 785-793, 6.2022
- Urheber
-
Vermunt, Marit A. C.
Nuland, Merel van
Heijden, Lisa T. van der
Rosing, Hilde
Beijnen, Jos. H.
Bergman, Andries M.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00280-022-04433-3
- URN
-
urn:nbn:de:101:1-2022072820024739056083
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:27 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Vermunt, Marit A. C.
- Nuland, Merel van
- Heijden, Lisa T. van der
- Rosing, Hilde
- Beijnen, Jos. H.
- Bergman, Andries M.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant Prostate Cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival
Ureter metastatic castration-resistant prostate cancer: a case report
JMJD2A participates in cytoskeletal remodeling to regulate castration-resistant prostate cancer docetaxel resistance
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting
Longitudinal CTCs gene expression analysis on metastatic castration-resistant prostate cancer patients treated with docetaxel reveals new potential prognosis markers
External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer
Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant Prostate Cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival
Ureter metastatic castration-resistant prostate cancer: a case report
JMJD2A participates in cytoskeletal remodeling to regulate castration-resistant prostate cancer docetaxel resistance
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting
Longitudinal CTCs gene expression analysis on metastatic castration-resistant prostate cancer patients treated with docetaxel reveals new potential prognosis markers
External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer
Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant Prostate Cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival
Ureter metastatic castration-resistant prostate cancer: a case report
JMJD2A participates in cytoskeletal remodeling to regulate castration-resistant prostate cancer docetaxel resistance
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting
Longitudinal CTCs gene expression analysis on metastatic castration-resistant prostate cancer patients treated with docetaxel reveals new potential prognosis markers
External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management